Results 51 to 60 of about 14,023 (271)

β‐secretase‐cleaved amyloid precursor protein in Alzheimer brain: a morphologic study [PDF]

Journal of Cellular and Molecular Medicine, 2004
Abstractβ‐amyloid (Aβ) is the main constituent of senile plaques seen in Alzheimer's disease. Aβ is derived from the amyloid precursor protein (APP) via proteolytic cleavage by proteases β‐ and β‐secretase. In this study, we examined content and localization of β‐secretase‐cleaved APP (β‐sAPP) in brain tissue sections from the frontal, temporal and ...
Sennvik, Kristina, Bogdanovic, N, Volkmann, Inga, Fastbom, J, Benedikz, Eirikur   +4 more
openaire   +3 more sources

Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism [PDF]

, 2017
Genome-wide association studies (GWASs) have identified 19 susceptibility loci for Alzheimer’s disease (AD). However, understanding how these genes are involved in the pathophysiology of AD is one of the main challenges of the “post-GWAS” era.
Cruchaga, Carlos, et al,, Goate, Alison M   +2 more
core   +4 more sources

Localization and regional distribution of p23/TMP21 in the brain

Neurobiology of Disease, 2008
Sequential processing of amyloid precursor protein by β- and γ-secretases generates Alzheimer's disease (AD)-associated β-amyloid peptides. Recently it was reported that the transmembrane protein p23/TMP21 associates with γ-secretase, and negatively ...
Kulandaivelu S. Vetrivel, Anitha Kodam, Ping Gong, Ying Chen, Angèle T. Parent, Satyabrata Kar, Gopal Thinakaran   +6 more
doaj   +1 more source

Determination of the proteolytic cleavage sites of the amyloid precursor-like protein 2 by the proteases ADAM10, BACE1 and γ-secretase. [PDF]

PLoS ONE, 2011
Regulated intramembrane proteolysis of the amyloid precursor protein (APP) by the protease activities α-, β- and γ-secretase controls the generation of the neurotoxic amyloid β peptide.
Sebastian Hogl, Peer-Hendrik Kuhn, Alessio Colombo, Stefan F Lichtenthaler   +3 more
doaj   +1 more source

-Secretase-Regulated Signaling Mechanisms: Notch and Amyloid Precursor Protein [PDF]

, 2012
In Drosophila, Notch mutations lost a lateral signaling ability and produced a neurogenic phenotype, where cells destined to become epidermis switch fate and give rise to neural tissue (Artavanis-Tsakonas et al. 1995; Lewis 1998). Therefore, when Notch signaling was disrupted, too many neurons were generated.
Nakayama, Kohzo, Nagase, Hisashi, Koh, Chang-Sung, Ohkawara, Takeshi   +3 more
openaire   +2 more sources

Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein [PDF]

Proceedings of the National Academy of Sciences, 2007
Proteolytic processing of the amyloid precursor protein (APP) by β-secretase, β-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid β (Aβ) peptide, which is involved in the pathogenesis of Alzheimer's disease.
Parkin, Ed, Watt, Nicole T., Hussain, Ishrut, Eckman, Elizabeth A., Eckman, Christopher B., Manson, Jean C., Baybutt, Herbert N., Turner, Anthony J., Hooper, Nigel M.   +8 more
openaire   +3 more sources

Role of membrane biophysics in Alzheimer\u27s–related cell pathways [PDF]

, 2015
Cellular membrane alterations are commonly observed in many diseases, including Alzheimer's disease (AD). Membrane biophysical properties, such as membrane molecular order, membrane fluidity, organization of lipid rafts, and adhesion between membrane and
Bungart, Brittani L, Lee, James C-M., Yang, Xiaoguang, Zhu, Donghui, Zhumadilov, Zhaxybay   +4 more
core   +8 more sources

SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein

Heliyon, 2018
Amyloid β, a key molecule in the pathogenesis of Alzheimer's disease (AD), is produced from amyloid precursor protein (APP) by the cleavage of secretases. APP is SUMOylated near the cleavage site of β-secretase.
Takuma Maruyama, Yoichiro Abe, Takako Niikura   +2 more
doaj   +1 more source

Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. [PDF]

PLoS ONE, 2011
BackgroundAlzheimer's disease (AD) is a neurodegenerative disorder that causes progressive memory and cognitive decline during middle to late adult life.
Naoki Yahata, Masashi Asai, Shiho Kitaoka, Kazutoshi Takahashi, Isao Asaka, Hiroyuki Hioki, Takeshi Kaneko, Kei Maruyama, Takaomi C Saido, Tatsutoshi Nakahata, Takashi Asada, Shinya Yamanaka, Nobuhisa Iwata, Haruhisa Inoue   +13 more
doaj   +1 more source

Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders

Neuroprotection, EarlyView.
The graphical abstract encapsulates the dual neuroprotective mechanisms of statins in neurodegenerative diseases, highlighting both cholesterol‐dependent and cholesterol‐independent pathways. By inhibiting 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, statins reduce cholesterol synthesis, leading to altered lipid raft structures that ...
Jun Han Kuan, Roshan S. Raghavan, Dawn Li Wei Koh, Wing Yeng Tan, Igor Iezhitsa, Renu Agarwal   +5 more
wiley   +1 more source